This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

RIKEN researchers have discovered how an enzyme modifies gene expression by targeting certain stretches of messenger RNA ...

Objectives The optimal maternal age at childbirth has been a topic of bourgeoning literature, with earlier ages offering physiological benefits for maternal recovery. In contrast, later ages to give ...

Explore the parallels and differences between AI architectures and the human brain's design and functionality in processing ...